RenasightIQ™: Kidney-native
clinicogenomic intelligence for biopharma
See your cohort in minutes. Follow it for years.
~100 biopharma companies work with Natera
325+ peer-reviewed publications
16M+ tests processed in CAP/CLIA-certified labs
Clinicogenomic intelligence, built for kidney drug development.
RenasightIQ links de-identified genomic, clinical, lab, and claims data for patients with CKD, followed over time. Build deeply profiled cohorts, see how they progress, and make development decisions faster, from discovery through launch.
One nephrology workflow, from cohort to execution.
One connected workflow, not a set of disconnected tools. Build a genetically defined CKD cohort in minutes. Follow it over time across genomic, clinical, lab, and claims data.
It’s self-serve, visual, and built to show how a population changes over time. The format kidney teams asked for: not 150 slides, not an endless spreadsheet.
-
DefineWho are my patients?
Patient Cohorting Dashboard
Build and size a genetically defined CKD cohort in minutes.
Filter by gene, variant, phenotype, labs, and comorbidity,
and see how the population progresses over time. -
SiteWhere do I run my trial?
Trial SiteID Dashboard
Pinpoint high-value trial sites and principal investigators based
on where your patients actually are. -
ProviderWho treats them?
Provider Insights Dashboard
Identify the providers and networks treating your target
population for trial and PI outreach.
Ready to explore? Move from planning to execution with RenasightIQ.
Request more information
Kidney programs need kidney-native data.
A traditional real-world database can tell you a patient has CKD. RenasightIQ decodes it: the gene, the variant, the trajectory.
Broad real-world data
Large, but generic.
Academic registries
Deep, but small.
RenasightIQ™
Kidney-native, genetically anchored, a complete clinical record.
Credible depth, at scale.
RenasightIQ is the largest genetically characterized CKD dataset, built from Renasight, the most widely used commercial genetic kidney panel.1
Final cohort
300K+
genomically characterized CKD patients, and growing
4-in-1
-
Genomic
-
Clinical
-
Lab
-
Claims
Followed over time in one connected dataset.
Scale a narrow panel can’t match
330+
genes with positive findings
~6%
dual-positive
28%
of positives outside APOL1 / PKD1-2 / COL4
Representativeness
30%
African ancestry
16.8%
Admixed American (Hispanic)
6.5%
Asian
Proof it moves programs forward.
ENYO · Alport syndrome (COL4)
Natera's patient matching team reached 100% of the target enrollment within 6 months, cutting enrollment time by 10 months and saving 25-33% of budget.
Purespring · (NPHS2)
RenasightIQ data found significant implications for NPHS2 in adults, reshaping the long-held belief that it only impacted pediatric patients. The findings were published a peer-review article in the Kidney International Reports.
Wherever you are in your program.
Define and size your population through target validation, natural history, and cohort definition.
RenasightIQ solutions:
- Patient Cohorting Dashboard
- Feasibility & Population
- Assessment Data Reports
Design and run the trial against a population you know exists through trial design information, site selection, patient enrollment, and comparator evidence.
RenasightIQ:
- Trial Site ID Dashboard
- Patient Matching
- Real-World Comparator Cohorts
Reach the right patients and prescribers through provider identification, and real-world utilization.
RenasightIQ solutions:
- Provider Insights Dashboard
- HEOR & Real-World Utilization
- Data Reports
Latest updates
Eledon
Prospera chosen as sole dd-cfDNA assay in Eledon's Phase 3 kidney transplant trial.
RenasightIQ Insight Report
A snapshot of hypertension (69%) and diabetes (32%) rates in ~211K CKD patients, segmented by age, sex, and state.
PKD Webinar
How longitudinal clinicogenomic data can improve patient identification and drug development in polycystic kidney disease.
Talk to our team.
Tell us what you're trying to answer in kidney disease, and we'll show you exactly where RenasightIQ™ fits.
Start self-serve.
Explore the dashboards on a trial: build cohorts, scope sites and map providers yourself.
Go deeper with data reports.
Commission a custom analytics analysis from our team for a specific research question.
Partner to execute.
Run trial enrollment with Natera-led patient matching with real-time visibility into how your trial is filling.
Reference:
- Natera. Data on File. 2026.